In this section
@inbook{Liew:2024:10.1183/2312508x.10021523,
author = {Liew, F and Openshaw, PJM},
booktitle = {COVID-19: An Update},
doi = {10.1183/2312508x.10021523},
editor = {Chalmers and Cilloniz and Cao},
pages = {250--277},
publisher = {European Respiratory Society},
title = {Long COVID: current management and future prospects},
url = {http://dx.doi.org/10.1183/2312508x.10021523},
year = {2024}
}
TY - CHAP
AB - Long COVID is a chronic and debilitating condition with limited treatment options, suffered by millions of people globally. In the absence of diagnostic biomarkers and defined pathobiological mechanisms, symptom control and rehabilitation are currently the mainstays of management. A variety of clinical trials are underway, but many fail to take into account the pathogenic subgroups of long COVID. Characterising these subgroups and elucidating their associated pathophysiology would enable targeted trials of disease-modifying treatments. Adaptive multidisciplinary trials using defined disease subgroups, biomarkers and end-points are required to optimise clinical interventions.
AU - Liew,F
AU - Openshaw,PJM
DO - 10.1183/2312508x.10021523
EP - 277
PB - European Respiratory Society
PY - 2024///
SN - 9781849841818
SP - 250
TI - Long COVID: current management and future prospects
T1 - COVID-19: An Update
UR - http://dx.doi.org/10.1183/2312508x.10021523
ER -
